{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:52Z","timestamp":1786982752714,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T00:00:00Z","timestamp":1568592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40259-019-00375-0","type":"journal-article","created":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T03:03:21Z","timestamp":1568603001000},"page":"571-579","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies"],"prefix":"10.1007","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct01968954","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5163-8993","authenticated-orcid":false,"given":"Ellen Q.","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.","family":"Bukowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Yunis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Shear","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela F.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Baltrukonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,16]]},"reference":[{"key":"375_CR1","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/MED.0000000000000242","volume":"23","author":"EA Stein","year":"2016","unstructured":"Stein EA. What role will proprotein convertase subtilisin\/kexin type 9 inhibitors play in hyperlipidemia management? Curr Opin Endocrinol Diabetes Obes. 2016;23:97\u2013105. https:\/\/doi.org\/10.1097\/MED.0000000000000242","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"key":"375_CR2","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/imj.13451","volume":"47","author":"DJ Scherer","year":"2017","unstructured":"Scherer DJ, Nelson AJ, Psaltis PJ, Nicholls SJ. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors. Intern Med J. 2017;47:856\u201365. https:\/\/doi.org\/10.1111\/imj.13451.","journal-title":"Intern Med J."},{"key":"375_CR3","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","volume":"114","author":"NG Seidah","year":"2014","unstructured":"Seidah NG, Awan Z, Chr\u00e9tien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022\u201336. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.301621.","journal-title":"Circ Res."},{"key":"375_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/clpt.2014.95","volume":"96","author":"J Vincent","year":"2014","unstructured":"Vincent J. Reducing elevated plasma LDL cholesterol: the central role of the LDL receptor. Clin Pharmacol Ther. 2014;96:3\u20137. https:\/\/doi.org\/10.1038\/clpt.2014.95.","journal-title":"Clin Pharmacol Ther."},{"key":"375_CR5","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/humu.20882","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264\u201372. https:\/\/doi.org\/10.1002\/humu.20882.","journal-title":"N Engl J Med."},{"key":"375_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/humu.20882","volume":"30","author":"M Abifadel","year":"2009","unstructured":"Abifadel M, Rabes JP, Devillers M, Munnich A, Erlich D, Junien C, et al. Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009;30:520\u20139.https:\/\/doi.org\/10.1002\/humu.20882.","journal-title":"Hum Mutat."},{"key":"375_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rab\u00e8s JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154\u20136. https:\/\/doi.org\/10.1038\/ng1161.","journal-title":"Nat Genet."},{"key":"375_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2013.01.044","volume":"228","author":"AL Catapano","year":"2013","unstructured":"Catapano AL, Papadopoulos N. The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis. 2013;228:18\u201328. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.01.044.","journal-title":"Atherosclerosis."},{"key":"375_CR9","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrcardio.2014.84","volume":"11","author":"RT Dadu","year":"2014","unstructured":"Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014;11:563\u201375. https:\/\/doi.org\/10.1038\/nrcardio.2014.84.","journal-title":"Nat Rev Cardiol."},{"key":"375_CR10","unstructured":"Amgen. REPATHA\u2122 (evolocumab) U.S. prescribing information. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125522s000lbl.pdf. Accessed 19 Sept 2018."},{"key":"375_CR11","unstructured":"Sanofi. PRALUENT\u2122 (alirocumab) prescribing information. 2015. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125559Orig1s000lbledt.pdf. Accessed 19 Sept 2018."},{"key":"375_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1124\/jpet.111.187419","volume":"340","author":"H Liang","year":"2012","unstructured":"Liang H, Chaparro-Riggers J, Strop P, Geng T, Sutton JE, Tsai D, et al. Proprotein convertase substilisin\/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther. 2012;340:228\u201336. https:\/\/doi.org\/10.1124\/jpet.111.187419.","journal-title":"J Pharmacol Exp Ther."},{"key":"375_CR13","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1016\/j.amjcard.2015.02.006","volume":"115","author":"CM Ballantyne","year":"2015","unstructured":"Ballantyne CM, Neutel J, Cropp A, Duggan W, Wang EQ, Plowchalk D, et al. Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia. Am J Cardiol. 2015;115:1212\u201321. https:\/\/doi.org\/10.1016\/j.amjcard.2015.02.006.","journal-title":"Am J Cardiol."},{"key":"375_CR14","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376:1527\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1701488.","journal-title":"N Engl J Med."},{"key":"375_CR15","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa1614062","volume":"376","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. N Engl J Med. 2017;376:1517\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1614062.","journal-title":"N Engl J Med."},{"key":"375_CR16","doi-asserted-by":"publisher","first-page":"e12278","DOI":"10.1111\/1755-5922.12278","volume":"35","author":"EQ Wang","year":"2017","unstructured":"Wang EQ, Plotka A, Salageanu J, Sattler C, Yunis C. Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301]. Cardiovasc Ther. 2017;35:e12278. https:\/\/doi.org\/10.1111\/1755-5922.12278.","journal-title":"Cardiovasc Ther."},{"key":"375_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/cts.12430","volume":"10","author":"M Levisetti","year":"2017","unstructured":"Levisetti M, Joh T, Wan H, Liang H, Forgues P, Gumbiner B, et al. A phase I randomized study of a specifically engineered, pH-sensitive PCSK9 inhibitor RN317 (PF-05335810) in hypercholesterolemic subjects on statin therapy. Clin Transl Sci. 2017;10:3\u201311. https:\/\/doi.org\/10.1111\/cts.12430.","journal-title":"Clin Transl Sci."},{"key":"375_CR18","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1253\/circj.CJ-16-1310","volume":"81","author":"K Yokote","year":"2017","unstructured":"Yokote K, Kanada S, Matsuoka O, Sekino H, Imai K, Tabira J, et al. Efficacy and safety of bococizumab (RN316\/PF-04950615), a monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, in hypercholesterolemic Japanese subjects receiving a stable dose of atorvastatin or treatment-naive- results from a randomized, placebo-controlled, dose-ranging study. Circ J. 2017;81:1496\u2013505. https:\/\/doi.org\/10.1253\/circj.CJ-16-1310.","journal-title":"Circ J."},{"key":"375_CR19","doi-asserted-by":"publisher","first-page":"e12308","DOI":"10.1111\/1755-5922.12308","volume":"36","author":"S Fazio","year":"2018","unstructured":"Fazio S, Robertson DG, Joh T, Wan H, Riel T, Forgues P, et al. Effects of 12\u00a0weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin\/kexin type 9, in hypercholesterolemic subjects on high-dose statin. Cardiovasc Ther. 2018;36:e12308. https:\/\/doi.org\/10.1111\/1755-5922.12308.","journal-title":"Cardiovasc Ther."},{"key":"375_CR20","doi-asserted-by":"publisher","first-page":"e12309","DOI":"10.1111\/1755-5922.12309","volume":"36","author":"B Gumbiner","year":"2018","unstructured":"Gumbiner B, Joh T, Liang H, Wan H, Levisetti M, Vana AM, et al. The effects of single- and multiple-dose administration of bococizumab (RN316\/PF-04950615), a humanized IgG2Deltaa monoclonal antibody binding proprotein convertase subtilisin\/kexin type 9, in hypercholesterolemic subjects treated with and without atorvastatin: results from four phase I studies. Cardiovasc Ther. 2018;36:e12309. https:\/\/doi.org\/10.1111\/1755-5922.12309.","journal-title":"Cardiovasc Ther."},{"key":"375_CR21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/cpdd.454","volume":"8","author":"EQ Wang","year":"2019","unstructured":"Wang EQ, Plotka A, Salageanu J, Baltrukonis D, Mridha K, Frederich R, et al. Comparative pharmacokinetics and pharmacodynamics of bococizumab following a single subcutaneous injection using drug substance manufactured at two sites or administration via two different devices. Clin Pharmacol Drug Dev. 2019;8:40\u20138. https:\/\/doi.org\/10.1002\/cpdd.454.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"375_CR22","unstructured":"Pfizer Inc. Pfizer discontinues global development of bococizumab, its investigational PCSK9 inhibitor. 2016. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_discontinues_global_development_of_bococizumab_its_investigational_pcsk9_inhibitor. Accessed 5 Dec 2016."},{"key":"375_CR23","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1161\/CIRCULATIONAHA.113.002033","volume":"127","author":"IN Foltz","year":"2013","unstructured":"Foltz IN, Karow M, Wasserman SM. Evolution and emergence of therapeutic monoclonal antibodies: what cardiologists need to know. Circulation. 2013;127:2222\u201330. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.002033.","journal-title":"Circulation."},{"key":"375_CR24","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1634\/theoncologist.2016-0061","volume":"21","author":"EM van Brummelen","year":"2016","unstructured":"van Brummelen EM, Ros W, Wolbink G, Beijnen JH, Schellens JH. Antidrug antibody formation in oncology: clinical relevance and challenges. Oncologist. 2016;21:1260\u20138. https:\/\/doi.org\/10.1634\/theoncologist.2016-0061.","journal-title":"Oncologist."},{"key":"375_CR25","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/nrd3229","volume":"9","author":"AL Nelson","year":"2010","unstructured":"Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov. 2010;9:767\u201374. https:\/\/doi.org\/10.1038\/nrd3229.","journal-title":"Nat Rev Drug Discov."},{"key":"375_CR26","unstructured":"Food and Drug Administration (FDA). Assay development and validation for immunogenicity testing of therapeutic protein products. Guidance for industry (draft). 2016. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM192750.pdf. Accessed 20 Apr 2017."},{"key":"375_CR27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1208\/s12248-014-9684-6","volume":"17","author":"MB Hock","year":"2015","unstructured":"Hock MB, Thudium KE, Carrasco-Triguero M, Schwabe NF. Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality. AAPS J. 2015;17:35\u201343. https:\/\/doi.org\/10.1208\/s12248-014-9684-6.","journal-title":"AAPS J."},{"key":"375_CR28","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.4155\/bio.14.283","volume":"6","author":"L Stevenson","year":"2014","unstructured":"Stevenson L, Amaravadi L, Myler H, Salazar-Fontana L, Gorovits B, Kirshner S, et al. 2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (part 3\u2014LBA and immunogenicity). Bioanalysis. 2014;6:3355\u201368. https:\/\/doi.org\/10.4155\/bio.14.283.","journal-title":"Bioanalysis."},{"key":"375_CR29","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.4155\/bio.13.10","volume":"5","author":"SA Hoofring","year":"2013","unstructured":"Hoofring SA, Lopez R, Hock MB, Kaliyaperumal A, Patel SK, Swanson SJ, et al. Immunogenicity testing strategy and bioanalytical assays for antibody-drug conjugates. Bioanalysis. 2013;5:1041\u201355. https:\/\/doi.org\/10.4155\/bio.13.10.","journal-title":"Bioanalysis."},{"key":"375_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ahj.2016.05.010","volume":"178","author":"PM Ridker","year":"2016","unstructured":"Ridker PM, Amarenco P, Brunell R, Glynn RJ, Jukema JW, Kastelein JJ, et al. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes trials. Am Heart J. 2016;178:135\u201344. https:\/\/doi.org\/10.1016\/j.ahj.2016.05.010.","journal-title":"Am Heart J."},{"key":"375_CR31","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","volume":"48","author":"G Shankar","year":"2008","unstructured":"Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48:1267\u201381. https:\/\/doi.org\/10.1016\/j.jpba.2008.09.020.","journal-title":"J Pharm Biomed Anal."},{"key":"375_CR32","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1208\/s12248-017-0148-7","volume":"19","author":"ZD Zhong","year":"2017","unstructured":"Zhong ZD, Clements-Egan A, Gorovits B, Maia M, Sumner G, Theobald V, et al. Drug target interference in immunogenicity assays: recommendations and mitigation strategies. AAPS J. 2017;19:1564\u201375. https:\/\/doi.org\/10.1208\/s12248-017-0148-7.","journal-title":"AAPS J."},{"key":"375_CR33","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1021\/bi7016359","volume":"47","author":"D Fan","year":"2008","unstructured":"Fan D, Yancey PG, Qiu S, Ding L, Weeber EJ, Linton MF, et al. Self-association of human PCSK9 correlates with its LDLR-degrading activity. Biochemistry. 2008;47:1631\u20139. https:\/\/doi.org\/10.1021\/bi7016359.","journal-title":"Biochemistry."},{"key":"375_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","volume":"157","author":"P Chames","year":"2009","unstructured":"Chames P, Van Regenmortel M, Weiss E, Baty D. Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol. 2009;157:220\u201333. https:\/\/doi.org\/10.1111\/j.1476-5381.2009.00190.x.","journal-title":"Br J Pharmacol."},{"key":"375_CR35","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/ard.2009.112847","volume":"69","author":"GM Bartelds","year":"2010","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010;69:817\u201321. https:\/\/doi.org\/10.1136\/ard.2009.112847.","journal-title":"Ann Rheum Dis."},{"key":"375_CR36","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0140-6736(09)60506-7","volume":"374","author":"JS Smolen","year":"2009","unstructured":"Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374:210\u201321. https:\/\/doi.org\/10.1016\/S0140-6736(09)60506-7.","journal-title":"Lancet."},{"key":"375_CR37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/ard.2010.135111","volume":"70","author":"A Jamnitski","year":"2011","unstructured":"Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg D, Stapel SO, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011;70:284\u20138. https:\/\/doi.org\/10.1136\/ard.2010.135111.","journal-title":"Ann Rheum Dis."},{"key":"375_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40259-015-0134-5","volume":"29","author":"SS Thomas","year":"2015","unstructured":"Thomas SS, Borazan N, Barroso N, Duan L, Taroumian S, Kretzmann B, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015;29:241\u201358. https:\/\/doi.org\/10.1007\/s40259-015-0134-5.","journal-title":"BioDrugs."},{"key":"375_CR39","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1136\/ard.2008.092833","volume":"68","author":"TR Radstake","year":"2009","unstructured":"Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1739\u201345. https:\/\/doi.org\/10.1136\/ard.2008.092833.","journal-title":"Ann Rheum Dis."},{"key":"375_CR40","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","volume":"50","author":"D Pascual-Salcedo","year":"2011","unstructured":"Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1445\u201352. https:\/\/doi.org\/10.1093\/rheumatology\/ker124.","journal-title":"Rheumatology (Oxford)."},{"key":"375_CR41","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","volume":"16","author":"G Shankar","year":"2014","unstructured":"Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 2014;16:658\u201373. https:\/\/doi.org\/10.1208\/s12248-014-9599-2.","journal-title":"AAPS J."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00375-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-019-00375-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00375-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T13:32:56Z","timestamp":1628602376000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-019-00375-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,16]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["375"],"URL":"https:\/\/doi.org\/10.1007\/s40259-019-00375-0","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,16]]},"assertion":[{"value":"16 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The SPIRE-HR study was funded by Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Ellen Q. Wang, Carla Yunis, Pamela F. Schwartz, and Daniel Baltrukonis are full-time employees of Pfizer. Jack F. Bukowski and Charles\u00a0L. Shear were employees of Pfizer at the time the study was conducted. Paul M. Ridker has acted as a consultant to Pfizer in relation to the SPIRE clinical trial program. Paul M. Ridker has received additional research grant support from Novartis, Amgen, and Kowa, and is listed as a co-inventor on patents held by the Brigham and Women\u2019s Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to AstraZeneca and Siemens.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}